Holding(s) in Company

Rhea-AI Summary

Amryt Pharma reported a significant change in major shareholdings as UBS Asset Management - O'Connor acquired a total of 6.13% voting rights in the company. This includes 2.60% direct voting rights from 4,229,753 shares and 3.53% from financial instruments. The change was effective as of September 22, 2020, and was officially notified on September 29, 2020. The investment reflects UBS Group AG's strategic interest in Amryt Pharma's potential growth and value in the market.

Positive

• UBS Asset Management - O'Connor acquired 6.13% total voting rights, indicating strong institutional interest in Amryt Pharma.
• The acquisition includes both 2.60% direct voting rights and 3.53% through financial instruments.

Negative

• None.

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Amryt Pharma PLC GB00BKLTQ412

1b. Please indicate if the issuer is a non-UK issuer  (please mark with an “X” if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an “X”)

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

UBS Asset Management - O'Connor UBS Group AG

City and country of registered office (if applicable)

Zürich, Switzerland

4. Full name of shareholder(s) (if different from 3.)v

Name

UBS O'Connor LLC

City and country of registered office (if applicable)

Wilmington, USA

5. Date on which the threshold was crossed or reachedvi:

22 September 2020

6. Date on which issuer notified (DD/MM/YYYY):

29 September 2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

2.60%

3.53%

6.13%

162'728'640

Position of previous notification (if applicable)

N/A

N/A

N/A

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type of shares ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BKLTQ412

4'229'753

2.60%

SUBTOTAL 8. A

4'229'753

2.60%

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expiration datex

Exercise/ Conversion Periodxi

Number of voting rights that may be acquired if the instrument is exercised/converted.

% of voting rights

US03217L1061

5'742'620

3.53%

SUBTOTAL 8. B 1

5'742'620

3.53%

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expiration datex

Exercise/ Conversion Period xi

Physical or cash settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)				X
Namexv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
UBS Group AG
UBS AG
UBS Americas Holding LLC
UBS O'Connor LLC	-	3.53%	6.13 %

10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional informationxvi

Place of completion	Opfikon, Switzerland
Date of completion	29.09.2020

FAQ

What was the recent major holding notification for Amryt Pharma (AMYT)?

UBS Asset Management - O'Connor reported acquiring a total of 6.13% voting rights in Amryt Pharma, effective September 22, 2020.

What percentage of voting rights does UBS Asset Management now hold in Amryt Pharma?

UBS Asset Management holds a total of 6.13% voting rights in Amryt Pharma, with 2.60% direct and 3.53% through financial instruments.

When was the acquisition of voting rights in Amryt Pharma reported?

The acquisition was officially notified on September 29, 2020.

What does the acquisition by UBS Asset Management indicate about Amryt Pharma?

The acquisition reflects strong institutional interest in Amryt Pharma's potential growth and market value.